First Time Loading...

CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 1.41 USD -0.7%
Updated: Jul 16, 2024
Have any thoughts about
CytomX Therapeutics Inc?
Write Note

Wall Street
Price Targets

CTMX Price Targets Summary
CytomX Therapeutics Inc

Wall Street analysts forecast CTMX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTMX is 5.42 USD with a low forecast of 3.54 USD and a high forecast of 8.4 USD.

Lowest
Price Target
3.54 USD
151% Upside
Average
Price Target
5.42 USD
285% Upside
Highest
Price Target
8.4 USD
496% Upside

CTMX Last Price Targets
CytomX Therapeutics Inc

The latest public price target was made on May 27, 2024 by Joseph Catanzaro from Piper Sandler , who expects CTMX stock to rise by 148% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Joseph Catanzaro
Piper Sandler
3.5 USD
Upside 148%
1 month ago
May 27, 2024
CytomX Therapeutics upgraded to Overweight from Neutral at Piper Sandler
TheFly
Robert Driscoll
Wedbush
8 USD
Upside 467%
2 months ago
May 9, 2024
Wedbush Upgrades CytomX Therapeutics (CTMX) to Outperform
StreetInsider
Etzer Darout
BMO Capital
3.59 USD
Upside 155%
2 months ago
May 9, 2024
CytomX Therapeutics (CTMX) PT Raised to $3.59 at BMO Capital
StreetInsider
Roger Song
Jefferies
8 USD
Upside 467%
2 months ago
May 5, 2024
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
TheFly
Roger Song
Jefferies
2.5 USD
Upside 77%
4 months ago
Mar 12, 2024
CytomX Therapeutics (CTMX) PT Raised to $2.50 at Jefferies, 'EGFRxCD3 on Track for Ph1a Data in 2H24'
StreetInsider
Etzer Darout
BMO Capital
3.25 USD
Upside 130%
4 months ago
Mar 12, 2024
CytomX Therapeutics (CTMX) PT Lowered to $3.25 at BMO Capital, 'Pipeline Updates Broadly in Line'
StreetInsider
Show More Price Targets
Show Less Price Targets
Joseph Catanzaro
Piper Sandler
Price Target 3.5 USD
Upside/Downside 148%
View Source
Robert Driscoll
Wedbush
Price Target 8 USD
Upside/Downside 467%
View Source
Etzer Darout
BMO Capital
Price Target 3.59 USD
Upside/Downside 155%
View Source
Roger Song
Jefferies
Price Target 8 USD
Upside/Downside 467%
View Source
Roger Song
Jefferies
Price Target 2.5 USD
Upside/Downside 77%
View Source
Etzer Darout
BMO Capital
Price Target 3.25 USD
Upside/Downside 130%
View Source
Show More Price Targets
Show Less Price Targets
CytomX Therapeutics Inc Competitors:
Price Targets
HALO
Halozyme Therapeutics Inc
10% Upside
MLYS
Mineralys Therapeutics Inc
134% Upside
AVCT
Avacta Group PLC
8% Downside
VYGR
Voyager Therapeutics Inc
100% Upside
048530
iNtRON Biotechnology Inc
153% Upside
DNLI
Denali Therapeutics Inc
65% Upside
1875
TOT BIOPHARM International Co Ltd
92% Upside
LEGN
Legend Biotech Corp
56% Upside

Revenue
Forecast

Revenue Estimate
CytomX Therapeutics Inc

For the last 8 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 38%. The projected CAGR for the next 3 years is -23%.

38%
Past Growth
-23%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
CytomX Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
CytomX Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-55%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CTMX's stock price target?
Price Target
5.42 USD

According to Wall Street analysts, the average 1-year price target for CTMX is 5.42 USD with a low forecast of 3.54 USD and a high forecast of 8.4 USD.

What is CytomX Therapeutics Inc's Revenue forecast?
Projected CAGR
-23%

For the last 8 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 38%. The projected CAGR for the next 3 years is -23%.